Navidea Biopharmaceuticals (NYSEMKT:NAVB) has shown a rise of 3.7% or 1,224,080 shares in the short positions. The bets have increased to 34,063,990 shares on June 15,2016 from 32,839,910 shares on May 31,2016. With respect to the floated shares, the shorts are 22.1%. The days to cover are calculated to be 27, using the standard per day volume of 1,271,259 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Navidea Biopharmaceuticals (NYSEMKT:NAVB): The stock opened at $0.64 on Friday but the bulls could not build on the opening and the stock topped out at $0.64 for the day. The stock traded down to $0.59 during the day, due to lack of any buying support eventually closed down at $0.59 with a loss of -10.25% for the day. The stock had closed at $0.66 on the previous day. The total traded volume was 13,049,633 shares.
The company shares have dropped -63.80% from its 1 Year high price. On Sep 21, 2015, the shares registered one year high at $2.50 and the one year low was seen on Jun 23, 2016. The 50-Day Moving Average price is $0.82 and the 200 Day Moving Average price is recorded at $1.04.
Navidea Biopharmaceuticals (NYSEMKT:NAVB) has tumbled 3.19% during the past week and has dropped 29.38% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.59%. Navidea Biopharmaceuticals (NYSEMKT:NAVB) has underperformed the index by 27.25% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimers disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinsons disease (PD) and other movement disorders.